Doubts persist for claimed Alzheimer's drug.

Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 0404511 Publication Model: Print Cited Medium: Internet ISSN: 1095-9203 (Electronic) Linking ISSN: 00368075 NLM ISO Abbreviation: Science Subsets: MEDLINE

Publication: : Washington, DC : American Association for the Advancement of Science
Original Publication: New York, N.Y. : [s.n.] 1880-

Drug Approval*; Alzheimer Disease/*therapy ; Amyloid beta-Peptides/*antagonists & inhibitors ; Antibodies, Monoclonal, Humanized/*adverse effects ; Antibodies, Monoclonal, Humanized/*therapeutic use; Apolipoprotein E4/genetics ; Brain Edema/etiology ; Brain Edema/genetics ; Clinical Trials as Topic ; Humans ; United States ; United States Food and Drug Administration

0 (Amyloid beta-Peptides)
0 (Antibodies, Monoclonal, Humanized)
0 (Apolipoprotein E4)
105J35OE21 (aducanumab)

Date Created: 20191214 Date Completed: 20200330 Latest Revision: 20200330

20231215

10.1126/science.366.6471.1298

31831649